Skip to main content
Terug
VRDN logo

Viridian Therapeutics, Inc.

Datakwaliteit: 100%
VRDN
NASDAQ Healthcare Biotechnology
€ 27,62
▲ € 0,64 (2,37%)
Marktkapitalisatie: 2,34B
Dagbereik
€ 27,25 € 28,30
52-Weeksbereik
€ 9,90 € 34,29
Volume
1.621.625
50D / 200D Gem.
€ 30,25 / € 24,06
Vorige Slotkoers
€ 26,98

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E -6,8 0,4
P/B 3,3 2,9
ROE % -49,2 3,8
Net Margin % -483,6 3,9
Rev Growth 5Y % 121,1 10,0
D/E 0,1 0,2

Koersdoel Analisten

Hold
€ 43,10 +56.0%
Low: € 34,00 High: € 50,00
Forward WPA
-€ 3,82
Omzet Sch.
75 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 4,62
€ 1,45 – € 10,66
1,3 B 4
FY2029 € 3,04
€ 0,95 – € 7,02
1 B 4
FY2028 € 0,81
-€ 3,32 – € 5,27
690 M 11

Belangrijkste Punten

Revenue grew 121,13% annually over 5 years — strong growth
Debt/Equity of 0,07 — conservative balance sheet
Negative free cash flow of -276,89M
PEG of 0,46 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 23238,80%
Capital efficient — spends only 0,70% of revenue on capex

Groei

Revenue Growth (5Y)
121,13%
Revenue (1Y)23359,93%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-49,16%
ROIC-35,26%
Net Margin-483,57%
Op. Margin-512,91%

Veiligheid

Debt / Equity
0,07
Current Ratio12,65
Interest Coverage-73,44

Waardering

P/E Ratio
-6,84
P/B Ratio3,25
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 23359,93% Revenue Growth (3Y) 1402,11%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 121,13% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 70,85M Net Income (TTM) -342,60M
ROE -49,16% ROA -38,09%
Gross Margin 98,36% Operating Margin -512,91%
Net Margin -483,57% Free Cash Flow (TTM) -276,89M
ROIC -35,26% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,07 Current Ratio 12,65
Interest Coverage -73,44 Dividend Yield 0,00%
Valuation
P/E Ratio -6,84 P/B Ratio 3,25
P/S Ratio 33,08 PEG Ratio 0,46
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 2,34B Enterprise Value 2,18B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 70,85M 302.000,0 314.000,0 1,77M 2,96M
Net Income -342,60M -269,95M -237,73M -129,87M -79,41M
EPS (Diluted) -3,32 -3,98 -5,31 -3,91 -6,66
Gross Profit 69,69M 302.000,0 314.000,0 1,77M 2,96M
Operating Income -363,40M -299,04M -254,45M -134,30M -79,73M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 899,42M 742,40M 490,42M 435,09M 203,71M
Total Liabilities 177,25M 70,76M 48,40M 40,03M 15,99M
Shareholders' Equity 722,17M 671,64M 442,02M 395,06M 187,72M
Total Debt 50,69M 21,10M 21,05M 5,26M 520.000,0
Cash & Equivalents 212,38M 99,59M 102,83M 155,58M 42,30M
Current Assets 894,23M 738,46M 486,48M 424,55M 200,16M
Current Liabilities 70,70M 47,87M 26,64M 33,35M 13,64M

Strategiescores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Full Throttle
#25 of 146
62

Recente Activiteit

Ingestapt Full Throttle
Mar 24, 2026